Benzinga | Aug 9, 2021 07:23AM EDT

Biohaven Pharmaceutical Q2 EPS $(2.62) Beats $(2.74) Estimate, Sales $92.93M Beat $78.13M Estimate

Biohaven Pharmaceutical (NYSE:BHVN) reported quarterly losses of $(2.62) per share which beat the analyst consensus estimate of $(2.74) by 4.38 percent. This is a 2.75 percent decrease over losses of $(2.55) per share from the same period last year. The company reported quarterly sales of $92.93 million which beat the analyst consensus estimate of $78.13 million by 18.95 percent. This is a 858.27 percent increase over sales of $9.70 million the same period last year.